z-logo
open-access-imgOpen Access
Genetics of Clozapine-Associated Neutropenia: Recent Advances, Challenges and Future Perspective
Author(s) -
Sophie E. Legge,
James Walters
Publication year - 2019
Publication title -
pharmacogenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 91
eISSN - 1744-8042
pISSN - 1462-2416
DOI - 10.2217/pgs-2018-0188
Subject(s) - clozapine , neutropenia , pharmacogenetics , genetic association , pharmacogenomics , medicine , etiology , antipsychotic , population , schizophrenia (object oriented programming) , bioinformatics , intensive care medicine , psychiatry , genotype , biology , genetics , single nucleotide polymorphism , gene , chemotherapy , environmental health
Clozapine is the only effective antipsychotic for treatment-resistant schizophrenia but remains widely under prescribed, at least in part due to its potential to cause agranulocytosis and neutropenia. In this article, we provide an overview of the current understanding of the genetics of clozapine-associated agranulocytosis and neutropenia. We now know that the genetic etiology of clozapine-associated neutropenia is complex and is likely to involve variants from several genes including HLA-DQB1, HLA-B and SLCO1B3/SLCO1B7. We describe recent findings relating to the Duffy-null genotype and its association with benign neutropenia in individuals with African ancestry. Further advances will come from sequencing studies, large, cross-population studies and in understanding the molecular mechanisms underlying these associations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom